Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month. The French drugmaker, whose shot uses the technology behind its licensed Japanese encephalitis vaccine, tested its vaccine in 153 adults with three dose levels based on a schedule of two doses with vaccinations three weeks apart… The vaccine, Valneva said, was “generally safe and well tolerated across all dose groups tested, with no safety concerns identified by an independent Data Safety Monitoring Board”.